Calling all patients and care partners to share their experiences to improve patient outcomes. The 2026 Global Patient Survey on Lymphoma & CLL(GPS) is the only opportunity for the worldwide lymphoma and CLL community of patients and care partners to share insights related to their experiences with lymphoma and CLL with the goal of improving patient care locally and globally.
CLL Canada is encouraging all patients and care partners to complete the GPS, including those who have participated before. Taking the time to do the survey every 2 years helps identify clinical trends over time, which can help other patients and care partners now and in the future.
What: 2026 Global Patient Survey on Lymphoma & CLL
Who: People living with lymphoma/CLL and care partners aged 18 & over
Time: ~ 40 minutes depending on experience with treatment and side effects
When: Now! Survey will be open till the end of March 2026
Why: To bring the voices and values of patients to lymphoma/CLL care, support, research and health policy
Lymphoma Coalition, together with member organizations, was one of the first global patient organizations to survey the experiences of patients and care partners. “It has now become a practice seen across the global cancer community” says Lorna Warwick, CEO of Lymphoma Coalition. “Since 2008, we update and launch the survey every two years so we can accurately represent current patients’ voices and values when we work with healthcare professionals, researchers, pharmaceutical companies, and others – ultimately building a better future for everyone with lymphoma and CLL.”
Lymphoma Coalition is a worldwide network of lymphoma and CLL patient organizations committed to bringing equity in lymphoma and CLL outcomes across borders. This is the 10th Global Patient Survey on Lymphoma & CLL, which is done biennially. Since its launch, more than 50,000 patients and care partners from 80+ countries have completed the survey. Find out more about the current and past surveys at www.lymphomacoalition.org/global-patient-survey.